NCT03934372 2025-12-17Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsIncyte CorporationPhase 1/2 Recruiting70 enrolled
NCT03576547 2025-05-08Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaM.D. Anderson Cancer CenterPhase 1/2 Terminated9 enrolled 11 charts